Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;12(1):100921.
doi: 10.1016/j.imr.2023.100921. Epub 2023 Jan 5.

Complementary and alternative medicine mention and recommendations in pancreatic cancer clinical practice guidelines: A systematic review and quality assessment

Affiliations
Review

Complementary and alternative medicine mention and recommendations in pancreatic cancer clinical practice guidelines: A systematic review and quality assessment

Jeremy Y Ng et al. Integr Med Res. 2023 Mar.

Abstract

Background: Pancreatic cancer is the third leading cause of cancer death in the United States, which is attributed to limited treatment options. Complementary and alternative medicine (CAM) therapies have been proposed to provide benefits in treating pancreatic cancer. Despite its importance in treatment, clinicians are not generally well equipped to counsel their patients about CAM therapies. This review identified the quantity and assessed the quality of clinical practice guidelines (CPGs) providing CAM recommendations for the treatment and/or management of pancreatic cancer.

Methods: A systematic review was conducted to identify pancreatic cancer CPGs. MEDLINE, EMBASE and CINAHL were searched from 2011 to 2022. The Guidelines International Network (GIN) and the National Center for Complementary and Integrative Health (NCCIH) websites were also searched. Eligible CPGs published by non-profit agencies on treatment and/or management of pancreatic cancer for adults were assessed using the Appraisal of Guidelines, Research and Evaluation II (AGREE II) instrument.

Results: From 31 eligible search results, 7 CPGs mentioned CAM and 3 CPGs made CAM recommendations. The mean scaled domain percentages of the CPGs in this study (overall, CAM-specific) were as follows: scope and purpose (81.3%, 77.8%), stakeholder involvement (63.9%, 42.6%), rigor-of-development (51.0%, 40.3%), clarity-of-presentation (83.3%, 54.6%), applicability (42.3%, 30.5%), and editorial independence (58.3%, 58.3%).

Conclusions: Evaluation of the CPGs demonstrated that quality varied both within and between CPGs. CPGs that scored well could be used by patients and clinicians as the basis for discussion for the use of CAM therapies. Future research should identify other appropriate CAM therapies for further development of CPGs for pancreatic cancer.

Registration: The protocol was registered on PROSPERO (registration number: CRD42022334025).

Keywords: AGREE II; Clinical practice guideline; Complementary and alternative medicine; Pancreatic cancer; Systematic review.

PubMed Disclaimer

Figures

Fig 1
Fig. 1
PRISMA Diagram.
Fig 2
Fig. 2
Summary of CAM Recommendations in Clinical Practice Guidelines for Pancreatic Cancer.

Similar articles

Cited by

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed
    1. Hussain S.P. Pancreatic Cancer: Current Progress and Future Challenges. Int J Biol Sci. 2016;12(3):270–272. doi: 10.7150/ijbs.14950. - DOI - PMC - PubMed
    1. Park W., Chawla A., O’Reilly E.M. Pancreatic Cancer: A Review. JAMA. 2021;326(9):851–862. doi: 10.1001/jama.2021.13027. - DOI - PMC - PubMed
    1. Arthur K., Belliard J.C., Hardin S.B., Knecht K., Chen C.S., Montgomery S. Reasons to Use and Disclose Use of Complementary Medicine Use – An Insight from Cancer Patients. Cancer Clin Oncol. 2013;2(2):81–92. doi: 10.5539/cco.v2n2p81. - DOI - PMC - PubMed

LinkOut - more resources